![]() |
![]() ![]() |
![]() |
![]() | ![]() ![]() ![]() |
![]() |
![]() |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
![]() ![]() ![]() | ![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
![]()
Feb. 1, 2023 - Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
Jan. 12, 2023 - Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference |
![]() |
![]() Upcoming EventsPast EventsJan. 19, 2023 - B. Riley Securities’ 3rd Annual Oncology ConferenceMore Dec. 6 - 10, 2022 - San Antonio Breast Cancer Symposium More Nov. 3, 2022 - Puma Biotechnology 3Q-2022 Financial Results Conference Call More Oct. 27, 2022 - EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium More Sept. 20, 2022 - Puma License Agreement for Alisertib More Sept. 12, 2022 - H.C. Wainwright 24th Annual Global Investment Conference More Sept. 11, 2022 - European Society for Medical Oncology (ESMO) Congress 2022 More |
![]() ![]() ![]() ![]() Annual Report Archives ![]() ![]() Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150 Los Angeles, CA 90024 424-248-6500 Main 424-248-6501 Fax Medical Inquiries: 1-844-MED-PUMA (1-844-633-7862), or medinfo@pumabiotechnology.com Business Development: info@pumabiotechnology.com Investor Relations: ir@pumabiotechnology.com ![]() Follow Us: |
![]() |
![]() © 2023 Puma Biotechnology, Inc. | Privacy Policy | Legal Notice | Site Map |